FY2030 Earnings Estimate for MSLE Issued By HC Wainwright

Satellos Bioscience Inc. (NASDAQ:MSLE) – Stock analysts at HC Wainwright upped their FY2030 earnings per share estimates for shares of Satellos Bioscience in a report issued on Monday, May 18th. HC Wainwright analyst A. He now expects that the company will earn $0.35 per share for the year, up from their previous forecast of $0.34. HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Satellos Bioscience’s current full-year earnings is ($2.29) per share.

Satellos Bioscience (NASDAQ:MSLE) last released its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02).

Other equities research analysts also recently issued reports about the company. Guggenheim initiated coverage on Satellos Bioscience in a research report on Tuesday, April 28th. They set a “buy” rating and a $23.00 price target on the stock. Zacks Research raised Satellos Bioscience to a “hold” rating in a research report on Tuesday, February 10th. Wall Street Zen raised Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research report on Saturday. Leerink Partners initiated coverage on Satellos Bioscience in a research report on Monday, April 6th. They set an “outperform” rating and a $20.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Monday, May 11th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Satellos Bioscience Stock Performance

NASDAQ MSLE opened at $7.15 on Tuesday. The firm has a fifty day moving average price of $7.41. Satellos Bioscience has a 1 year low of $4.53 and a 1 year high of $13.39. The firm has a market cap of $148.93 million, a P/E ratio of -4.47 and a beta of 1.60.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.